Specific Changes in Vitamin D Receptor Protein Linked to MS Risk, Study Suggests

Specific Changes in Vitamin D Receptor Protein Linked to MS Risk, Study Suggests
3.8
(9)

A risk of multiple sclerosis rises in people with specific variations in a protein, called the vitamin D receptor, that affects how this vitamin works and is metabolized in the body, a study drawn from a meta-analysis reports.

Its researchers suggest these variations, or changes within the protein, play a role in MS development.

Their study, “Association between vitamin D receptor (VDR) polymorphisms and the risk of multiple sclerosis (MS): an updated meta-analysis,” was published in the journal BMC Neurology.

Vitamin D is thought to be able to mitigate the risks of being diagnosed with MS. Studies have shown that people with this disease have lower serum vitamin D levels compared to healthy controls.

In the body, vitamin D modulates the immune system by binding to the vitamin D receptor (VDR). Variations in the VDR’s amino acid sequence — the building blocks of proteins — are related to changes in vitamin D’s function and metabolism. 

These VDR variations — known as polymorphisms — may be connected to MS. As a result, many studies have sought to find a link.

However, multiple reviews (meta-analysis) of published studies also reported contradictory results. Some meta-analyses concluded that VDR variation plays a role in MS, while others did not. 

As the strength of any one meta-analysis is based on which particular studies are reviewed, new studies can strengthen the analysis and provide more clarity. 

A research team in Iran, aware of newly published work, conducted a fresh meta-analysis into the possible association between VDR variation and MS risk.

“Since publishing of the last meta-analysis, seven new studies have been founded in electronic databases. Therefore, we conducted a meta-analysis of all eligible published case-control studies to obtain an exact evaluation of the association between VDR gene polymorphisms and susceptibility to MS,” the researchers wrote.

VDR variation was evaluated by a technique called restriction fragment length polymorphisms, in which a group of enzymes, called restriction enzymes, are used to cut the VDR gene into pieces. The resulting fragments are then analyzed. 

These enzymes are sensitive to small changes in the gene sequence, so different VDR variants can be identified by different fragment patterns generated by a specific restriction enzyme. Digestion of the VDR gene with four of such enzymes — BsmI, ApaI, FokI, and TaqI — produced unique fragment patterns, each representing a single VDR variant (named after each enzyme).

The team reviewed a total of 30 studies.

Results showed a significant association between the TaqI variant and MS risk. No elevated overall risk was found in people with BsmI, ApaI, and FokI variants. 

A further analysis based on the geographical location found that in Asian populations the BsmI variant was linked to an increase in MS risk, while ApaI was associated with a lesser risk.

No link was found between any of these variants and MS risk in European populations. 

The Fok1 variant was not associated with a greater disease risk overall, or by geographical region. 

A final statistical analysis found no evidence of publication bias, which can occur if some reviewed studies are selected over others, demonstrating that this meta-analysis was a good representation of the available evidence, the team reported.

“This meta-analysis suggested a significant association between TaqI polymorphism and MS susceptibility,” its researchers wrote.

However, “future large-scale studies on gene-environment and gene-gene interactions are required to estimate related risk factors, and assist early diagnosis of patients at high risk for MS,” they concluded.

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • relapse
  • cognition and MS
  • immune cells
  • vascular disease risk

How useful was this post?

Click on a star to rate it!

Average rating 3.8 / 5. Vote count: 9

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?